Etamicastat

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-(2-oxoimidazolidin-1-yl)phenyl]methyl]pyrrolidine-1-carboximidamide | image = Etamicastat_structure.png | width = 250 | CAS_number = 118292-40-7 | ATC_prefix = none | PubChem = 6918495 | ChemSpiderID = 5293730 | UNII = 8X3J3V0U7M | KEGG = D09950 | ChEMBL = 2103870 | C=15 | H=20 | N=4 | O=1 | smiles = C1CC(N(C1)C(=N)N)CC2=CC=C(C=C2)N3C(=O)NCC3 | StdInChI = 1S/C15H20N4O/c16-15(17)19-10-4-5-11(19)9-12-1-3-13(8-14(12)20)18-6-7-21-18/h1,3,8,11H,4-7,9-10H2,(H3,16,17) | StdInChIKey = ZQXJXKQZKJQZQK-UHFFFAOYSA-N }}

Etamicastat is a pharmaceutical compound that acts as an inhibitor of the enzyme dopamine beta-hydroxylase (DBH). This enzyme is responsible for the conversion of dopamine to norepinephrine, a key neurotransmitter in the sympathetic nervous system. By inhibiting DBH, etamicastat reduces the production of norepinephrine, which can have various therapeutic effects, particularly in the treatment of hypertension.

Mechanism of Action

Etamicastat works by selectively inhibiting the activity of dopamine beta-hydroxylase. This enzyme is located in the synaptic vesicles of adrenergic neurons and is crucial for the biosynthesis of norepinephrine from dopamine. By blocking this conversion, etamicastat decreases the levels of norepinephrine available for release into the synaptic cleft, thereby reducing sympathetic nervous system activity. This reduction in sympathetic tone can lead to a decrease in blood pressure, making etamicastat a potential treatment for hypertension.

Pharmacokinetics

The pharmacokinetic profile of etamicastat involves its absorption, distribution, metabolism, and excretion. After oral administration, etamicastat is absorbed into the bloodstream and distributed throughout the body. It is metabolized primarily in the liver, and its metabolites are excreted via the kidneys. The half-life of etamicastat allows for once-daily dosing, which can improve patient compliance.

Clinical Applications

Etamicastat has been investigated for its potential use in treating hypertension, particularly in patients who may benefit from reduced sympathetic nervous system activity. Clinical trials have shown that etamicastat can effectively lower blood pressure in hypertensive patients. However, its use is still under investigation, and it is not yet widely available as a treatment option.

Side Effects

As with any medication, etamicastat can have side effects. Common side effects include dizziness, fatigue, and gastrointestinal disturbances. These are generally mild and transient. However, because etamicastat affects norepinephrine levels, it may also cause orthostatic hypotension, a condition where blood pressure drops significantly upon standing, leading to dizziness or fainting.

Research and Development

Etamicastat is still under research and development, with ongoing studies to better understand its efficacy and safety profile. Researchers are also exploring its potential use in other conditions where modulation of norepinephrine levels might be beneficial, such as heart failure and certain psychiatric disorders.

Also see

• Dopamine beta-hydroxylase
• Norepinephrine
• Hypertension
• Sympathetic nervous system